Dihexa vs Noopept
Emerging vs Moderate Research
compatible Some stack for cognition; limited safety data.
Molecular Data
Dihexa Noopept
Weight 504.7 Da 318.37 Da
Half-life 8-12 days ~30 minutes (oral), active metabolite cycloprolylglycine persists longer
Type Modified oligopeptide Dipeptide derivative (C17H22N2O4)
Key Benefits
Dihexa
01 Dramatic synaptogenesis promotion
02 10 million times more potent than BDNF
03 Cognitive enhancement and memory improvement
04 Neuroprotection and potential neuroregeneration
05 Applications for Alzheimer's, TBI, age-related cognitive decline
06 Oral bioavailability
Noopept
01 Enhanced memory formation and consolidation through upregulation of BDNF and NGF
02 Neuroprotective effects against oxidative stress, excitotoxicity, and amyloid-beta toxicity
03 Improved learning capacity and information retrieval via AMPA/NMDA receptor modulation
04 Ultra-low effective dose (10-30 mg) compared to classical racetams, reducing pill burden and cost
05 Anxiolytic properties observed at standard nootropic doses without sedation
06 Fast onset of subjective effects despite the short parent compound half-life, due to active metabolite persistence
Dosing Protocols
Dihexa
8-10mg oral or 2-5mg injectable (0.5mg/kg based on research) / Once daily in the morning
Research protocol 0.5mg/kg daily Daily or 3x weekly
Standard injectable 2-5mg total 1x daily
Noopept
10-30 mg/day / Split AM/PM (sublingual or oral)
Side Effects
Dihexa
Headaches (most frequent side effect)
Anxiety or overstimulation
Sleep disruption when dosed late in day
Mental clarity increase
Noopept
Headache (most common side effect, typically caused by insufficient choline intake -- co-supplementation with Alpha-GPC or CDP-Choline usually resolves this)
Irritability and restlessness, particularly at doses exceeding 30 mg/day
Insomnia if taken too late in the day
Mild gastrointestinal discomfort when taken on an empty stomach
Contraindications
Not FDA approved - research compound only
Theoretical cancer risk via c-Met activation
Cancer history (avoid due to c-Met pathway)
Pregnancy or breastfeeding
No long-term human safety data
Known hypersensitivity to Noopept or related compounds
Severe hepatic impairment (metabolized by the liver)
Severe renal impairment
Pregnancy and breastfeeding (insufficient safety data)
Hypertension that is poorly controlled (due to potential mild pressor effects)
Research Evidence
Dihexa Noopept
Status Emerging Moderate Research
References 4 studies 4 studies
Latest 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.